RxDoctor Payments Data

Barbara Ray, MD

Family Medicine · Gaffney, SCNPI 1225095243

Payments from drug & device makers

$6,715in general payments, 2019–2025

Across 374 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$726
  • Amgen$567
  • Pfizer$559
  • Novo Nordisk$447
  • Lilly USA, LLC$314
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,715 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$21,842
Medicare patients
47
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen389$271,445
OzempicSemaglutide101$99,756
FarxigaDapagliflozin Propanediol110$83,917
ProlateOxycodone Hcl/Acetaminophen12$37,514
LinzessLinaclotide49$32,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,549
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$27,971
JardianceEmpagliflozin46$26,771
MounjaroTirzepatide25$26,674
TrulicityDulaglutide13$20,801
XareltoRivaroxaban33$19,492
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen383$16,489
VraylarCariprazine Hcl11$16,450
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,518
Albuterol Sulfate HfaAlbuterol Sulfate173$4,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,277$111,888150 claims
Novo NordiskOzempic$447$99,756101 claims
AbbVieLinzess, Vraylar$726$48,94260 claims
Lilly USA, LLCMounjaro, Trulicity$314$47,47538 claims
GSKTrelegy Ellipta, Anoro Ellipta$229$45,06872 claims
Forte Bio-pharma LLCProlate$274$37,51412 claims
Boehringer IngelheimJardiance$152$26,77146 claims
Johnson & JohnsonXarelto$12$19,49233 claims
PfizerPremarin$559$3,97414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Gaffney

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →